Vir Biotechnology, Inc. last reported quarterly results on Nov 4, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $188,000 (-178.3% year over year) and diluted EPS of -$0.57. It usually reports 12–36 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–36 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 4, 2026
35 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
-0
-178.3%
|
-96
+41.0%
|
-0.57
+51.3%
|
|
Aug 5, 2026
36 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
239
+19582.5%
|
80
+172.2%
|
0.47
+158.8%
|
|
May 6, 2026
36 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
-0
-101.0%
|
-126
-3.9%
|
-0.85
+3.4%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
64
+417.8%
|
-43
+59.0%
|
-0.31
+59.7%
|
|
Nov 5, 2025
36 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
0
-89.9%
|
-163
+23.7%
|
-1.17
+25.0%
|
|
Aug 6, 2025
37 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
1
-60.5%
|
-111
+19.8%
|
-0.80
+21.6%
|
|
May 7, 2025
37 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
3
-94.6%
|
-121
-85.3%
|
-0.88
-83.3%
|
|
Feb 26, 2025
57 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
12
-26.3%
|
-105
+9.8%
|
-0.76
+11.3%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- VIR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Francisco, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1706431
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.